While the survival of patients with certain cancer types can be extended by these inhibitors, such as in patients with advanced BRAFV600-mutated melanoma [63], cardiotoxicity and drug resistance are frequent and severe side effects of prolonged treatment with FDA-approved drugs that target Raf/MEK/ERK1/2 signaling in cancer. This evidence concerns the gene MAPK3 and cancer.